← Back to Search

Tyrosine Kinase Inhibitor

Immunotherapy for Advanced Rare Cancers

Phase 2
Waitlist Available
Research Sponsored by Canadian Cancer Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 months
Awards & highlights

Study Summary

This trial is testing a new immunotherapy treatment for cancer that has not responded to other treatments.

Who is the study for?
This trial is for patients with advanced rare tumors who have measurable disease, are over 16 years old (or over 5 for a specific cohort), and have an ECOG performance status of 0-2. They should not have received certain prior treatments and must meet lab requirements. Exclusions include cardiovascular issues, recent heart or brain events, inability to absorb oral meds, known drug sensitivities, other cancer histories or concurrent cancer treatments.Check my eligibility
What is being tested?
The study tests Sunitinib and Temsirolimus in patients with no cure-available cancers to see if these drugs can shrink the tumors. It's a Phase II trial which means it's checking the effectiveness of these drugs on this particular type of tumor after initial safety has been established.See study design
What are the potential side effects?
Potential side effects may include high blood pressure; bleeding or clotting problems; weak immune system leading to infections; liver issues; fatigue; mouth sores; nausea and vomiting. Specific to Sunitinib: heart problems, thyroid changes. For Temsirolimus: rash, elevated blood sugar levels.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response
Secondary outcome measures
Efficacy Outcomes
Safety Monitoring
Translational Research

Trial Design

2Treatment groups
Active Control
Group I: SunitinibActive Control1 Intervention
Group II: TemsirolimusActive Control1 Intervention

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,568 Previous Clinical Trials
10,911,749 Total Patients Enrolled
4 Trials studying Tumors
1,873 Patients Enrolled for Tumors
Canadian Cancer Trials GroupLead Sponsor
124 Previous Clinical Trials
67,316 Total Patients Enrolled
Hal HirteStudy ChairJuravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON Canada
1 Previous Clinical Trials
59 Total Patients Enrolled

Media Library

Sunitinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01396408 — Phase 2
Tumors Research Study Groups: Sunitinib, Temsirolimus
Tumors Clinical Trial 2023: Sunitinib Highlights & Side Effects. Trial Name: NCT01396408 — Phase 2
Sunitinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01396408 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
2012. "A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01396408.
All > Sutent
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top